-       Company secures € 15 million loan
-       Plans remain on track for rights offering later this year

Planegg/Munich (Germany), July 23, 2010 – Agennix AG (Frankfurt Stock Exchange: AGX) today provided an update on its near-term financing plans.  The Company announced that it has entered into an agreement with one of its major shareholders, dievini Hopp BioTech holding GmbH & Co. KG, pursuant to which dievini Hopp BioTech has provided a € 15.0 million loan to Agennix at an interest rate of 6% per annum.  The loan agreement is unsecured and is repayable on thirty days advance notice, but not before October 15, 2010. As previously disclosed, the Company also plans to execute a rights equity offering, as resolved in its annual shareholders’ meeting in May 2010.

Torsten Hombeck, Ph.D., Chief Financial Officer of Agennix, said:  “We are on track with our plans to undertake later this year the major capital increase that was resolved by our shareholders’ meeting. With the loan in place, we can focus our efforts on finalizing the preparations for the planned rights offering as well as on continuing to advance our clinical trials. The € 15 million from this loan, together with our existing cash balance, is expected to fund the Company’s operations into the fourth quarter of 2010.”

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies to improve the length and quality of life of seriously ill patients in areas of major unmet medical need. The Company’s most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix’s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. There can be no guarantee that the planned rights offering will be completed in a timely manner, if at all, nor that the Company will have sufficient cash to advance its operations.  Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

This press release is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States of America. The shares in Agennix AG (the “Shares”) mentioned herein may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act").

The Shares have not been, and will not be, registered under the Securities Act and will not be offered or sold in the United States, except on the basis of applicable exemptions from registration. There will be no public offering of securities in the United States.